Minsky B D
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Oncology (Williston Park). 1996 Nov;10(11):1701-8, 1713-4; discussion 1714-18.
The standard adjuvant therapy for resectable T3 and/or N1-2 rectal cancer is pelvic radiation therapy plus fluorouracil (5-FU)-based chemotherapy. Two randomized intergroup trials, INT 0114 and INT 0144, will help determine the ideal chemotherapeutic agents and their routes of administration in the postoperative setting. The randomized National Surgical Adjuvant Project for Breast and Bowel Cancers trial NSABP R-03 and the INT 0147 trial will compare the efficacy and functional results of the preoperative and postoperative combined-modality therapy approaches. The delivery of effective therapies, as well as the development of more innovative approaches, is enhanced by a multidisciplinary collaboration among medical, surgical, and radiation oncologists.
可切除的T3和/或N1 - 2期直肠癌的标准辅助治疗是盆腔放疗加基于氟尿嘧啶（5 - FU）的化疗。两项随机组间试验，INT 0114和INT 0144，将有助于确定术后环境中理想的化疗药物及其给药途径。乳腺癌和结直肠癌国家外科辅助项目随机试验NSABP R - 03和INT 0147试验将比较术前和术后综合治疗方法的疗效和功能结果。医学、外科和放射肿瘤学家之间的多学科合作加强了有效治疗的提供以及更创新方法的开发。
